Active Filter(s):
Details:
DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, which is investigated in combination with eflornithine in patients newly diagnosed with glioblastoma.
Lead Product(s): Eflornithine,Temozolomide
Therapeutic Area: Oncology Product Name: DFMO
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.
Lead Product(s): Eflornithine
Therapeutic Area: Rare Diseases and Disorders Product Name: DFMO
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Michigan State University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2023
Details:
Enrollment of patients in Phase 3 STELLAR trial for DFMO (eflornithine hydrochloride), a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase in patients in patients with recurrent anaplastic astrocytoma.
Lead Product(s): Eflornithine,Lomustine
Therapeutic Area: Oncology Product Name: DFMO
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.
Lead Product(s): Eflornithine,Lomustine
Therapeutic Area: Oncology Product Name: DFMO
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Patent relates to a solution of eflornithine for oral administration currently being evaluated in Orbus’ Phase 3 STELLAR study in rare brain cancer.
Lead Product(s): Eflornithine,Lomustine
Therapeutic Area: Oncology Product Name: DFMO
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
The expanded Series A funding will support the ongoing STELLAR study, a Phase 3 clinical trial studying eflornithine in patients with anaplastic astrocytoma whose cancer has recurred following radiation and adjuvant chemotherapy.
Lead Product(s): Eflornithine,Lomustine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Longitude Capital
Deal Size: $71.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 22, 2020